Heparin Dosage Calculation Examples

Calculate precise heparin dosing for therapeutic anticoagulation based on patient weight, indication, and renal function

Comprehensive Guide to Heparin Dosage Calculation

Heparin remains one of the most commonly used anticoagulants in clinical practice due to its rapid onset of action and reversibility. Proper dosing is critical to balance therapeutic efficacy with bleeding risk. This guide provides evidence-based recommendations for heparin dosage calculations across various clinical scenarios.

Understanding Heparin Types

Two main types of heparin are used clinically:

1. Unfractionated Heparin (UFH): Requires frequent monitoring (aPTT) and dose adjustments due to variable pharmacokinetics. Typically administered as an intravenous bolus followed by continuous infusion.
2. Low Molecular Weight Heparin (LMWH): Includes enoxaparin, dalteparin, and tinzaparin. Offers more predictable anticoagulant response with once- or twice-daily subcutaneous dosing and generally doesn’t require routine monitoring.

Key Factors in Heparin Dosing

• Patient Weight: Most heparin dosing is weight-based (units/kg). Obese patients may require adjusted dosing based on ideal body weight or adjusted body weight.
• Renal Function: LMWHs are primarily renally cleared. Dose reduction is required in renal impairment (CrCl <30 mL/min).
• Indication: Dosing varies significantly between treatment (e.g., PE, DVT) and prophylaxis (e.g., post-op, medical patients).
• Bleeding Risk: Patients with high bleeding risk (e.g., recent surgery, active GI bleed) may require lower doses or alternative agents.

Standard Dosing Protocols

Indication	UFH Bolus	UFH Infusion	LMWH Dosing	Monitoring
VTE Treatment	80 units/kg (max 8,000 units)	18 units/kg/hr (max 1,800 units/hr)	1 mg/kg SC q12h or 1.5 mg/kg SC q24h	aPTT q6h until therapeutic (1.5-2.5× control)
VTE Prophylaxis (Medical)	N/A	N/A	40 mg SC q24h or 30 mg SC q12h	None required for standard doses
ACS (NSTEMI/UA)	60-70 units/kg (max 5,000 units)	12-15 units/kg/hr (max 1,000 units/hr)	1 mg/kg SC q12h	aPTT q6h (target 1.5-2.0× control)
AFib with PCI	60-100 units/kg (max 10,000 units)	12-15 units/kg/hr during procedure	Not typically used	ACT monitoring during procedure

Special Populations

Obese Patients

For patients with BMI >40 kg/m²:

• UFH: Use adjusted body weight (ABW) = IBW + 0.4 × (actual weight – IBW)
• LMWH: Use actual body weight (maximum 150 mg for enoxaparin)

Renal Impairment

LMWH accumulation occurs with CrCl <30 mL/min:

CrCl (mL/min)	Enoxaparin Dose Adjustment	Dalteparin Dose Adjustment
≥30	No adjustment	No adjustment
15-30	Reduce by 25-30%	Reduce by 25%
<15	Avoid or use UFH with monitoring	Avoid or use UFH with monitoring

Monitoring Parameters

Unfractionated Heparin:

• aPTT: Target 1.5-2.5× control (typically 46-70 seconds). Check 6 hours after bolus, then q6h until stable ×2, then daily.
• Anti-Xa: Alternative for patients with lupus anticoagulant (target 0.3-0.7 IU/mL).

Low Molecular Weight Heparin:

• Routine monitoring not required for most patients.
• Consider anti-Xa levels (target 0.5-1.0 IU/mL) for:
• Pregnant patients
• Morbid obesity (BMI >40)
• Renal impairment (CrCl <30)
• Pediatric patients

Common Clinical Scenarios

Venous Thromboembolism (VTE) Treatment

For a 70 kg patient with normal renal function:

• UFH: 5,600 unit bolus (80 units/kg), then 1,260 units/hr (18 units/kg/hr)
• Enoxaparin: 70 mg SC q12h or 105 mg SC q24h
• Duration: Minimum 5 days, with transition to warfarin (INR 2-3) or DOAC when appropriate

Atrial Fibrillation with PCI

For a 80 kg patient undergoing cardiac catheterization:

• UFH Bolus: 6,000-8,000 units (75-100 units/kg)
• ACT Target: 250-300 seconds for PCI, 300-350 seconds for complex procedures
• Post-PCI: Continue infusion at 12-15 units/kg/hr if additional anticoagulation needed

Safety Considerations

Heparin-Induced Thrombocytopenia (HIT):

• Monitor platelet counts daily between days 4-14 of therapy.
• Suspect HIT with platelet count drop >50% from baseline or to <150,000/μL.
• If HIT confirmed, discontinue all heparin and initiate alternative anticoagulant (e.g., argatroban, bivalirudin).

Bleeding Complications:

• Major bleeding occurs in ~2-5% of patients on therapeutic heparin.
• Risk factors: advanced age, renal impairment, concomitant antiplatelet therapy, recent surgery.
• Protamine sulfate can reverse UFH (1 mg protamine per 100 units heparin).
• LMWH is only partially reversible with protamine (60-75% for enoxaparin).

Transitioning to Oral Anticoagulants

When converting from heparin to warfarin:

1. Start warfarin on day 1 of heparin therapy.
2. Continue heparin for minimum 5 days AND until INR ≥2.0 for 24 hours.
3. For DOACs (apixaban, rivaroxaban, edoxaban, dabigatran):
• Start DOAC 0-2 hours before next scheduled LMWH dose or at time of stopping UFH infusion.
• For dabigatran in CrCl 30-50 mL/min, reduce dose to 75 mg BID.

Pediatric Heparin Dosing

Neonates and children require different dosing due to developmental hemostasis:

• UFH Bolus: 75 units/kg
• UFH Infusion: 28 units/kg/hr for infants <1 year; 20 units/kg/hr for children >1 year
• aPTT Target: 60-85 seconds (1.5-2.5× normal)
• LMWH: Enoxaparin 1 mg/kg/dose q12h for infants <2 months; 1.5 mg/kg/day for older children

Emerging Alternatives to Heparin

While heparin remains standard, several alternatives exist for specific situations:

• Fondaparinux: Synthetic pentasaccharide that inhibits factor Xa. Used for VTE prophylaxis/treatment in HIT patients (2.5 mg SC daily for prophylaxis; weight-based for treatment).
• Argatroban: Direct thrombin inhibitor for HIT patients (initial dose 2 mcg/kg/min, adjust to aPTT 1.5-3× baseline).
• Bivalirudin: Alternative for PCI in HIT patients (0.75 mg/kg bolus, then 1.75 mg/kg/hr infusion).

Authoritative Resources

American Society of Hematology: Heparin Dosing and Monitoring Guidelines American College of Cardiology: Antithrombotic Therapy for VTE Disease NIH National Heart, Lung, and Blood Institute: Venous Thromboembolism Treatment